4-异丁基苯硼酸频那醇酯 | 1033753-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-异丁基苯硼酸频那醇酯
• 中文别名: 4-异丁基苯基硼酸，频哪醇酯
• 英文名称: 4,4,5,5-tetramethyl-2-(4-isobutylphenyl)-1,3,2-dioxaborolane
• 英文别名: 4,4,5,5-tetramethyl-2-[4-(2-methylpropyl)phenyl]-1,3,2-dioxaborolane；2-(4-isobutylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS: 1033753-01-3
• 化学式: C₁₆H₂₅BO₂
• 分子量: 260.184
• InChiKey: HBCAMNZOIJNSQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  应存于室温、密封、干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Isobutylphenylboronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
May cause long lasting harmful effects to aquatic life
H413:

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Isobutylphenylboronic acid, pinacol ester
CAS number: 1033753-01-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H25BO2
Molecular weight: 260.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-异丁基苯硼酸频那醇酯 、 二氯碘硝基苯 在 [1,1'-二(二叔丁基膦)二茂铁]合二氯钯(II) 、 potassium carbonate 作用下， 以 水 为溶剂， 生成 2,6-dichloro-4'-isobutyl-4-nitro-1,1'-biphenyl
  参考文献：
  名称：

  发现联芳酰胺衍生物作为癌症免疫治疗的有效、选择性和口服生物可利用的 RORγt 激动剂

  摘要：

  主转录因子受体视黄酸受体相关孤儿受体 γt (RORγt) 调节辅助 T 17 (Th17) 细胞的分化和白细胞介素 17 (IL-17) 的产生。肿瘤微环境中RORγt + T细胞的激活促进免疫浸润，更有效地抑制肿瘤生长。因此，RORγt激动剂为癌症免疫治疗提供了一种可行的方法。在此，设计、合成并评估了一系列作为新型 RORγt 激动剂的联芳酰胺衍生物。从报道的 RORγt 反向激动剂 GSK805 开始 ( 1 )，“功能转换”和基于结构的药物优化导致发现了一种有前途的 RORγt 激动剂先导化合物14 ，该化合物表现出有效和选择性的 RORγt 激动剂活性，并显着提高了代谢稳定性。化合物14具有出色的体内药代动力学特征，在小鼠 B16F10 黑色素瘤和 LLC 肺腺癌的临床前肿瘤模型中表现出强大的功效。总而言之，当前的研究表明14值得进一步研究作为癌症免疫治疗的潜在主要 RORγt 激动剂。

  DOI：

  10.1021/acs.jmedchem.3c01492
• 作为产物：
  描述：

  1-溴-4-异丁基苯 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-异丁基苯硼酸频那醇酯
  参考文献：
  名称：

  发现联芳酰胺衍生物作为癌症免疫治疗的有效、选择性和口服生物可利用的 RORγt 激动剂

  摘要：

  主转录因子受体视黄酸受体相关孤儿受体 γt (RORγt) 调节辅助 T 17 (Th17) 细胞的分化和白细胞介素 17 (IL-17) 的产生。肿瘤微环境中RORγt + T细胞的激活促进免疫浸润，更有效地抑制肿瘤生长。因此，RORγt激动剂为癌症免疫治疗提供了一种可行的方法。在此，设计、合成并评估了一系列作为新型 RORγt 激动剂的联芳酰胺衍生物。从报道的 RORγt 反向激动剂 GSK805 开始 ( 1 )，“功能转换”和基于结构的药物优化导致发现了一种有前途的 RORγt 激动剂先导化合物14 ，该化合物表现出有效和选择性的 RORγt 激动剂活性，并显着提高了代谢稳定性。化合物14具有出色的体内药代动力学特征，在小鼠 B16F10 黑色素瘤和 LLC 肺腺癌的临床前肿瘤模型中表现出强大的功效。总而言之，当前的研究表明14值得进一步研究作为癌症免疫治疗的潜在主要 RORγt 激动剂。

  DOI：

  10.1021/acs.jmedchem.3c01492

文献信息

• Mechanistic Studies into Amine-Mediated Electrophilic Arene Borylation and Its Application in MIDA Boronate Synthesis
  作者：Viktor Bagutski、Alessandro Del Grosso、Josue Ayuso Carrillo、Ian A. Cade、Matthew D. Helm、James R. Lawson、Paul J. Singleton、Sophia A. Solomon、Tommaso Marcelli、Michael J. Ingleson

  DOI：10.1021/ja3100963

  日期：2013.1.9

  computational study, the borylation of activated arenes at 20 °C proceeds through an S(E)Ar mechanism with borenium cations, [Y(2)B(amine)](+), the key electrophiles. For catecholato-borocations, two amine dependent reaction pathways were identified: (i) With [CatB(NEt(3))](+), an additional base is necessary to accomplish rapid borylation by deprotonation of the borylated arenium cation (σ complex), which otherwise

  使用 Y(2)BCl (Y(2) = Cl(2) 或邻儿茶酚) 与等摩尔 AlCl(3) 和叔胺直接亲电硼化已应用于广泛的芳烃和杂芳烃。使用 TMS(2)MIDA 可以对 ArBCl(2) 产品进行原位功能化，以中等至良好的产率提供工作台稳定且易于分离的 MIDA 硼酸盐。根据一项联合实验和计算研究，在 20 °C 下活化芳烃的硼酸化通过 S(E)Ar 机制与硼阳离子 [Y(2)B(胺)](+) 进行，这是关键的亲电子试剂。对于儿茶酚 - 硼阳离子，确定了两种胺依赖性反应途径：（i）使用 [CatB（NEt（3））]（+），需要额外的碱来通过硼化砷阳离子（σ复合物）的去质子化来实现快速硼化, 否则宁愿分解为起始材料，也不愿释放游离胺以实现去质子化。除了胺之外，额外的碱也可以是芳烃本身，当它足够碱性时（例如，N-Me-吲哚）。(ii) 当硼阳离子的胺组分亲核性较低时（例如，2,6-二甲基吡啶
• Iron-catalysed enantioselective Suzuki–Miyaura coupling of racemic alkyl bromides
  作者：Takahiro Iwamoto、Chiemi Okuzono、Laksmikanta Adak、Masayoshi Jin、Masaharu Nakamura

  DOI：10.1039/c8cc09523j

  日期：——

  facile access to various optically active α-arylpropionic acids including several nonsteroidal anti-inflammatory drugs (NSAIDs) of commercial importance. (R,R)-QuinoxP* is specifically able to induce chirality when compared to analogous P-chiral ligands that give racemic products, highlighting the critical importance of transmetalation in the present asymmetric cross-coupling system.

  已经开发出第一个铁催化的对映选择性的Suzuki-Miyaura偶联反应。在催化量的FeCl 2和（R，R）-QuinoxP *的存在下，芳基硼酸锂与α-溴丙酸叔丁酯以对映体会聚方式交叉偶联，从而可以轻松获得各种旋光性α-芳基丙酸，包括几种具有商业重要性的非甾体抗炎药（NSAIDs）。与产生外消旋产物的类似P-手性配体相比，（R，R）-QuinoxP *特别能够诱导手性，突出了在当前的不对称交叉偶联系统中金属转移的关键重要性。
• 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物
  申请人：杭州中美华东制药有限公司

  公开号：CN117658947A

  公开（公告）日：2024-03-08

  本发明涉及一类具有蛋白酪氨酸磷酸酶抑制作用的化合物或其药学上可接受的盐，及其在制备治疗蛋白酪氨酸磷酸酶异常表达相关疾病的药物中的应用。具体涉及式(I)所示化合物及其药学上可接受的盐。#imgabs0#
• Isocytosine-based inhibitors of xanthine oxidase: Design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia
  作者：Smriti Khanna、Sandeep Burudkar、Komal Bajaj、Pranay Shah、Ashish Keche、Usha Ghosh、Avani Desai、Ankita Srivastava、Asha Kulkarni-Almeida、Nitin J. Deshmukh、Amol Dixit、Manoja K. Brahma、Umakant Bahirat、Lalit Doshi、Kumar V.S. Nemmani、Prashant Tannu、Anagha Damre、Chandrika B-Rao、Rajiv Sharma、H. Sivaramakrishnan

  DOI：10.1016/j.bmcl.2012.10.029

  日期：2012.12

  Structure-activity relationship studies were carried out for lead generation following structure-guided design approach from an isocytosine scaffold identified earlier for xanthine oxidase inhibition. A 470-fold improvement in in vitro IC50 was obtained in the process. Five most potent compounds with nanomolar IC50 values were selected for pharmacokinetics and in vivo experiments. The best compound showed good in vivo activity when administered intraperitoneally but was not active by oral route. The results suggest that improvement in oral exposure could improve the in vivo efficacy of this series. (C) 2012 Elsevier Ltd. All rights reserved.
• Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy
  作者：Lixue Lu、Yafei Huang、Meiqi Song、Nannan Sun、Li Xia、Mingcheng Yu、Meiling Zhao、Ruomeng Qiu、Ji-an Chen、Yunpeng Zhao、Haojie Wang、Huimin Guo、Yan Li、Di Zhu、Yonghui Wang、Qiong Xie

  DOI：10.1021/acs.jmedchem.3c01492

  日期：2023.12.14

  immunotherapy. Herein, a series of biaryl amide derivatives as novel RORγt agonists were designed, synthesized, and evaluated. Starting from the reported RORγt inverse agonist GSK805 (1), “functionality switching” and structure-based drug optimization led to the discovery of a promising RORγt agonist lead compound 14, which displayed potent and selective RORγt agonist activity and significantly improved metabolic

  主转录因子受体视黄酸受体相关孤儿受体 γt (RORγt) 调节辅助 T 17 (Th17) 细胞的分化和白细胞介素 17 (IL-17) 的产生。肿瘤微环境中RORγt + T细胞的激活促进免疫浸润，更有效地抑制肿瘤生长。因此，RORγt激动剂为癌症免疫治疗提供了一种可行的方法。在此，设计、合成并评估了一系列作为新型 RORγt 激动剂的联芳酰胺衍生物。从报道的 RORγt 反向激动剂 GSK805 开始 ( 1 )，“功能转换”和基于结构的药物优化导致发现了一种有前途的 RORγt 激动剂先导化合物14 ，该化合物表现出有效和选择性的 RORγt 激动剂活性，并显着提高了代谢稳定性。化合物14具有出色的体内药代动力学特征，在小鼠 B16F10 黑色素瘤和 LLC 肺腺癌的临床前肿瘤模型中表现出强大的功效。总而言之，当前的研究表明14值得进一步研究作为癌症免疫治疗的潜在主要 RORγt 激动剂。